Success Metrics

Active Trials

10(77%)

Phase Distribution

Ph phase_2

46%

Ph phase_1

54%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

7(53.8%)

Phase 2Efficacy & side effects

6(46.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(12)

Other(1)

Detailed Status

Recruiting10

Not yet recruiting2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 17 (53.8%)

Phase 26 (46.2%)

Trials by Status

not_yet_recruiting215%

unknown18%

recruiting1077%

Recent Activity

10 active trials

Showing 5 of 13

recruitingphase_2

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

NCT07229729

recruitingphase_1

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

NCT07059221

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT06649331Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting

NCT07414953Phase 1

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not Yet Recruiting

NCT05076682Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

NCT07229729Phase 2

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Recruiting

NCT07059221Phase 1

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Recruiting

NCT05701709Phase 1

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Recruiting

NCT07041437Phase 2

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

Not Yet Recruiting

NCT06895928Phase 2

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting

NCT06417554Phase 1

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Recruiting

NCT06639347Phase 1

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting

NCT06589778Phase 1

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

NCT05594095Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting

NCT05735275Phase 1

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Unknown

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13